AI assistant
PTC THERAPEUTICS, INC. — Director's Dealing 2021
Feb 10, 2021
31046_dirs_2021-02-10_cc10cf85-7c3a-4521-93f5-4a4ef802e107.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2021-02-08
Reporting Person: Utter Christine Marie (SVP, Finance & CAO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-08 | Common Stock | M | 2657 | $33.02 | Acquired | 19166 | Direct |
| 2021-02-08 | Common Stock | S | 2657 | $66.00 | Disposed | 16509 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-08 | Stock Option (Right to Buy) | $33.02 | M | 2657 | Disposed | 2029-01-21 | Common Stock (2657) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right To Buy) | $490.8 | 2021-04-27 | Common Stock (74.0) | 74 | Direct |
| Stock Option (Right To Buy) | $218.4 | 2022-01-10 | Common Stock (21.0) | 21 | Direct |
| Stock Option (Right To Buy) | $40.45 | 2024-09-23 | Common Stock (4688.0) | 4688 | Direct |
| Stock Option (Right To Buy) | $51.0 | 2025-01-02 | Common Stock (17800.0) | 17800 | Direct |
| Stock Option (Right to Buy) | $18.01 | 2028-01-02 | Common Stock (10000) | 10000 | Direct |
| Stock Option (Right To Buy) | $33.02 | 2029-01-21 | Common Stock (10100.0) | 10100 | Direct |
| Stock Option (Right To Buy) | $51.16 | 2030-01-28 | Common Stock (23800.0) | 23800 | Direct |
| Stock Option (Right to Buy) | $66.49 | 2031-01-05 | Common Stock (50750) | 50750 | Direct |
Footnotes
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 14, 2020.
F2: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F3: Currently exercisable.
F4: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
F5: This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
F6: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
F7: Represents an option award of 33,250 options and an option award of 17,500 options. These option awards were each granted on January 6, 2021, and each vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.